Is Compounded Semaglutide Still Legal in 2026?

For most of 2022 through 2024, compounded semaglutide was everywhere: telehealth sites, med spas, and weight-loss memberships sold it at a fraction of the brand-name price. That market existed for one specific legal reason, and that reason is now gone. The semaglutide shortage that made compounding permissible ended in February 2025, and the legal runway for pharmacies to keep making copies ran out a few months later. If you are searching whether compounded semaglutide is still legal, the honest answer in 2026 is: not the way it was, and not as a routine product.

A note before the details. A lot of older articles, and a lot of current marketing, still frame compounded semaglutide as "legal because of the shortage." That framing is out of date. The rest of this page walks through what actually changed, what narrow exception survives, and what is still unsettled in court.

Why compounded semaglutide was allowed at all

Compounding is the practice of a licensed pharmacy preparing a medication for a patient. It runs on two sections of federal law: 503A (traditional pharmacies compounding for individual patients) and 503B (registered outsourcing facilities that can make larger batches). This is the same 503A/503B framework that governs peptide compounding.

Normally, a pharmacy cannot compound a copy of a commercially available, FDA-approved drug. The major exception is when that approved drug is on the FDA's official shortage list. Injectable semaglutide, sold as the FDA-approved brands Ozempic and Wegovy, was added to the shortage list in early 2022 as demand exploded. That listing is what opened the door: while the brand was in shortage, compounders could legally fill the gap.

The compounded market that grew up around that exception was enormous. It was always conditional, though. It depended entirely on the shortage continuing.

What changed: the shortage ended

Once Novo Nordisk's manufacturing caught up with demand, the exception's foundation disappeared.

• December 19, 2024: the FDA declared the tirzepatide (Mounjaro/Zepbound) shortage resolved.
• February 21, 2025: the FDA declared the semaglutide shortage resolved and removed all doses of injectable semaglutide from the shortage list.
• Pharmacies got a short wind-down window, not an immediate cutoff. For semaglutide, the 503A deadline was April 22, 2025 and the 503B deadline was May 22, 2025. (Tirzepatide's deadlines were February 19 and March 19, 2025.)

After those dates, the FDA's enforcement discretion ended. A drug that is no longer in shortage is, once again, a drug that pharmacies generally may not copy.

Where it stands now (mid-2026)

• Outsourcing facilities (503B): effectively closed. The drugs are off the shortage list, and on April 30, 2026 the FDA went further and proposed to keep semaglutide, tirzepatide, and liraglutide off the 503B "bulks" list, concluding there is no clinical need that justifies it. Cost and convenience, the agency said, are not clinical need. That proposal published in the Federal Register on May 1, 2026, with a public comment window open through June 30, 2026. It is a proposal, not yet final, but it signals the direction clearly.
• Traditional pharmacies (503A): a narrow door remains open. A prescriber can document, for a specific patient, a genuine clinical reason that a compounded version is meaningfully different from the approved product, for example a real medical need for a different formulation. This is individualized and must be documented on the prescription. It is not a license for a standardized, sign-up-online compounded product.
• "Personalized" combinations (semaglutide plus B12, for instance) and salt forms (semaglutide sodium or acetate) are not reliable workarounds. The FDA treats a combination that mirrors the approved drug as still essentially a copy, and it considers the salt forms to be different active ingredients with no compliant basis for compounding.

What is still unsettled

Two honest caveats keep this from being a closed book:

1. It is on appeal. The Outsourcing Facilities Association sued the FDA over the shortage determinations. Trial courts declined to block the FDA in both the tirzepatide and semaglutide cases, and the consolidated appeal was argued before the Fifth Circuit on March 25, 2026. As of this writing there is no decision. The wind-down is in effect, but the underlying legal question is not finally settled.
2. The 503B exclusion is a proposal. The April 30, 2026 action is a proposed determination with a comment period, not a finalized rule. The likely direction is clear, but it has not been completed.

When the courts or the FDA actually decide something, that decision, not the marketing around it, is what changes the law.

The safety record the FDA points to

The legal change did not happen in a vacuum. The FDA has pointed to a specific safety record for compounded GLP-1s:

• Dosing errors. Because some compounded products require patients to measure their own doses from a vial, the FDA documented cases of people taking five to twenty times the intended dose, with adverse events including severe nausea and vomiting, dehydration, fainting, and acute pancreatitis, some serious enough to require hospitalization.
• Different active ingredients. The agency has warned that "semaglutide sodium" and "semaglutide acetate" are not the same active ingredient as the approved semaglutide base.
• Counterfeits. Counterfeit "Ozempic" has been seized inside the U.S. drug supply chain more than once.

These are the agency's stated concerns. They are reported here as context for the regulatory change, not as a verdict on any individual product or pharmacy.

If your compounded supply is ending

If you have been on compounded semaglutide and your pharmacy is winding it down, the practical question becomes a tracking problem. You may be switching to a brand-name pen, moving to a different dose ladder, or pausing while you sort out coverage, and each of those changes is exactly the kind of thing worth keeping a clean private record of.

That is the part Regimio is built for. The GLP-1 tracker keeps your dose history, your titration steps, your injection sites, and your weight trend on your phone, with no account and nothing uploaded. When you talk to a prescriber about a clinical-need exception, a coverage appeal, or a dose change, walking in with your actual logged history is far stronger than trying to remember it. The record is yours, and it stays on your device.

This article reports the regulatory status of compounded semaglutide as of mid-2026 and summarizes safety findings published by the FDA. It is not medical or legal advice, and it does not recommend any compound, product, pharmacy, or source. The law in this area is actively changing and partly on appeal; confirm current status with primary sources, and make decisions about any therapy with a clinician who knows your history.